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Abstract
Cigarette smoking increases the likelihood of developing anxiety disorders, among them panic disorder (PD). While brain
structures altered by smoking partly overlap with morphological changes identified in PD, the modulating impact of
smoking as a potential confounder on structural alterations in PD has not yet been addressed. In total, 143 PD patients (71
smokers) and 178 healthy controls (62 smokers) participated in a multicenter magnetic resonance imaging (MRI) study.
T1-weighted images were used to examine brain structural alterations using voxel-based morphometry in a priori defined
regions of the defensive system network. PD was associated with gray matter volume reductions in the amygdala and
hippocampus. This difference was driven by non-smokers and absent in smoking subjects. Bilateral amygdala volumes were
reduced with increasing health burden (neither PD nor smoking > either PD or smoking > both PD and smoking). As
smoking can narrow or diminish commonly observed structural abnormalities in PD, the effect of smoking should be
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considered in MRI studies focusing on patients with pathological forms of fear and anxiety. Future studies are needed to
determine if smoking may increase the risk for subsequent psychopathology via brain functional or structural alterations.
Key words: smoking; gray matter volume; panic disorder; amygdala; hippocampus
Introduction
Smoking behavior is overrepresented in patients with mental
disorders in general (Lasser et al., 2000; Cook et al., 2014) and
in patients with anxiety disorders particularly (Johnson et al.,
2000). Among anxiety disorders, panic disorder (PD) is linked to
cigarette smoking in many epidemiological investigations using
cross-sectional designs (Goodwin and Hamilton, 2002; Lawrence
et al., 2010). Prospective epidemiological studies support smoking
to increase the likelihood of developing panic attacks and PD
(Breslau and Klein, 1999; Johnson et al., 2000; Isensee et al., 2003;
Breslau et al., 2004). Furthermore, PD patients who smoke report
significantly more intense anxiety symptoms and greater sever-
ity of panic symptoms than those who do not smoke (Zvolen-
sky et al., 2005). In addition, they show increased problems
to stop smoking compared to healthy smokers (Piper et al.,
2010). However, while the link between smoking and PD is well
established epidemiologically, its neurobiological basis remains
mostly unclear.
Persistent smoking has been related to a number of structural
brain changes following nicotine consumption, as demonstrated
by previous cross-sectional studies (Brody et al., 2004; Gallinat
et al., 2006; Zhang et al., 2011; Liao et al., 2012; Pan et al., 2013; Fritz
et al., 2014). Voxel-based morphometry (VBM) analyses found
reduced gray matter volumes (GMV) in the anterior cingulate
cortex (ACC; Brody et al., 2004; Yu et al., 2011; Liao et al., 2012), the
dorsolateral prefrontal cortex (Brody et al., 2004; Gallinat et al.,
2006; Liao et al., 2012; Fritz et al., 2014), the orbitofrontal cortex
(OFC; Kühn et al., 2010; Morales et al., 2012; Fritz et al., 2014), the
fusiform gyrus (Gallinat et al., 2006), the cerebellum (Brody et al.,
2004; Kühn et al., 2012) and in the left thalamus (Liao et al., 2012;
Hanlon et al., 2016). Associations between cigarette smoking
and brain volumes were also identified for striatal nuclei, with
smaller nucleus accumbens volumes (Das et al., 2012) and greater
putamen volumes (Das et al., 2012; Franklin et al., 2014) in oth-
erwise healthy smokers. Contradictory evidence is available for
amygdala volume, where Durazzo et al. (2017) reported smaller
GMV, whereas Shen et al. (2017) did not find any differences in
healthy smokers vs non-smokers.
Neural system models for PD emphasize altered functional-
ity of a network conferring defensive reactivity, which encom-
passes the insula, ACC, thalamus, hippocampus, amygdala and
regions of the brain stem (midbrain, periaqueductal gray; Dresler
et al., 2013). Structural alterations have been reported for limbic
structures (amygdala, hippocampus), cortical areas (ACC), the
brain stem (midbrain, pons), basal ganglia (caudate, putamen)
and the thalamus (Massana et al., 2003; Uchida et al., 2003;
Asami et al., 2009; Hayano et al., 2009; Del Casale et al., 2013;
Dresler et al., 2013). Reduced volumes of cortico-limbic structures
were associated with PD symptoms and maintenance (Dresler
et al., 2013). It appears that brain structural abnormalities in
smokers substantially overlap with those associated with PD
pathophysiology in terms of fronto-limbic circuits (e.g. ACC,
amygdala). As smoking behavior is overrepresented among PD
patients, it may represent a potential confounder. Thus, differ-
ences between PD patients and healthy controls (HC) may have
been over- or underestimated in previous investigations as a
result of smoking. The same may be true for studies compar-
ing PD patients with other patient groups with lower smoking
prevalence.
Only a handful of neuroimaging studies have focused
on understanding the neural mechanisms of smoking and
comorbid mental illness, and the majority of these studies have
concentrated on comorbid schizophrenia (Tregellas et al., 2007;
Schneider et al., 2014; Jørgensen et al., 2015). No investigation has
previously examined the effect of smoking on brain morphology
in patients with PD. For those areas, overlapping in both
conditions, it is unclear whether smoking enhances or obscures
the effect of PD.
To address this issue, we here intended to further clarify
the modulating impact of smoking on brain morphological cor-
relates in PD patients free of psychopharmacotherapy. First,
we aimed to confirm smoking effects on brain morphology in
healthy smokers and non-smokers. Second, based on the above-
cited VBM studies, we hypothesized GMV reductions in fronto-
limbic circuitry, frequently observed as a feature of PD patho-
physiology, may be partly driven by differential rates in smok-
ing behaviors. Third, we examined a possible additive effect of
smoking on brain morphology in PD patients.
Materials and methods
Participants
The study was part of the German national research network
PANIC-NET (second funding period). Magnetic resonance
imaging (MRI) measurements were conducted in five German
centers (Marburg, Berlin, Dresden, Greifswald and Muenster),
which are participating centers for the national research
initiative PANIC-NET (funded by the German Federal Ministry
of Education and Research, BMBF). These centers have a
long-standing tradition of collaborative multicenter functional
magnetic resonance imaging (fMRI) studies (e.g. Kircher et al.,
2013). The current analysis encompasses a post-hoc research
question supplementing the main study outcomes. In total,
157 PD patients and 187 HC subjects underwent MRI scanning.
Inclusion criteria for patients were as follows: (i) a current DSM-
IV-TR (Diagnostic and Statistical Manual of Mental Disorders 4th
Edition) primary diagnosis of PD (American Psychiatric Associa-
tion, 2000) evidenced by the Composite International Diagnostic
Interview (CAPI-WHO-CIDI; DIAX-CIDI version) and validated by
clinical experts; (ii) a score≥3 on the Clinical Global Impressions
Scale and (iii) an age of 18–65 years. Exclusion criteria were as
follows: (i) comorbid DSM-IV-TR psychotic or bipolar I disorder;
(ii) current alcohol dependence/current abuse or dependence
on benzodiazepine and other psychoactive substances; (iii)
current suicidal intent; (iv) borderline personality disorder; (v)
concurrent ongoing psychopharmacological treatment for PD or
another mental disorder and (vi) antidepressant or anxiolytic
pharmacotherapy. The HC group was free of current or past
medical, neurological or mental illness as evidenced by a
clinical interview. Additional MRI-related exclusion criteria
such as ferromagnetic metal implants applied to both groups.







/scan/article/15/8/849/5878977 by guest on 16 February 2021
Table 1. Sociodemographic characteristics of the smoker and non-smoker sample and clinical characteristics of the PD patients sample, only
Smokers, mean +/− s.d. or no. (%) n=133 Non-smokers, mean +/− s.d. or no. (%) n=188
Sociodemographic characteristics










Age [mean (s.d.)] 34.13 (10.7) 31.23 (9.5) 1.643 0.103 33.18 (11.3) 31.85 (10.8) 0.804 0.423
Female gender [n (%)] 45 (63) 34 (55) 1.001 0.317 44 (61) 67 (58) 0.206 0.650
Years of education [n (%)]
8 5 (7) 0 10.413 0.005 4 (6) 1 (1) 16.427 <0.001
10 23 (32) 10 (16) 26 (36) 17 (15)
12–13 43 (61) 52 (84) 42 (58) 97 (84)
Right-handedness [n (%)] 69 (97) 62 (100) 0.904 0.342 69 (96) 112 (97) 0.850 0.654
Clinical characteristics
PD patients, mean +/− s.d. or no. (%) n=143 HC subjects, mean +/− s.d. or no. (%) n=178












SIGH-A 20.4 (7.6) 18.6 (8.8) 1.276 0.204 2.3 (2.3) 1.8 (2.1) 1.170 0.244
ASI 32.8 (11.5) 30.0 (11.5) 1.449 0.150 10.31 (6.3) 10.0 (6.7) 0.305 0.761
BSI 62.4 (32.9) 51.6 (34.0) 1.900 0.060 6.9 (7.1) 8.0 (9.2) −0.735 0.453
BDI 14.8 (8.5) 12.3 (8.3) 1.760 0.081 2.2 (2.9) 2.0 (2.6) 0.374 0.709
MI total 2.2 (0.9) 2.1 (0.7) 0.851 0.396
MI AAC 1.9 (0.9) 1.8 (0.7) 0.653 0.515
MI AAL 2.5 (0.9) 2.4 (0.9) 0.782 0.436
CGI 4.5 (1.2) 4.2 (0.9) 1.530 0.128
PAS 23.2 (8.5) 21.7 (9.4) 0.994 0.322
Comorbid DEP 32 (45.10) 19 (26.39) 5.437 0.020
Comorbid diagnoses 1.54 (1.34) 1.14 (1.43) 1.70 0.10
Nicotine dependencea 20 (28.17) 6 (8.33)
Notes: PD, panic disorder; HC, healthy controls; CGI, Clinical Global Impression Scale; SIGH-A, Hamilton Anxiety Scale; PAS, Panic and Agoraphobia Scale; ASI, Anxiety
Sensitivity Index; BDI-II, Beck Depression Inventory; BSI, Brief Symptom Inventory; MI total, Mobility Inventory total score; MI AAC, Mobility Inventory Avoidance
Accompanied; MI AAL, Mobility Inventory Avoidance alone; DEP, depressive disorders.
Missing values in HC subjects: SIGH-A: 15 S, 33 NS; ASI: 11 S, 6 NS; BSI: 11 S, 7 NS.
aThe diagnosis of nicotine dependence is based on the 12-month prevalence assessed by the CIDI interview, the six subjects in the non-smoker group can be
characterized as ex-smoker.
self-report and compared with 12-month DSM-IV-TR diagnosis
of nicotine dependence in the PD group, assessed in the clinical
interview. After exclusion of participants with missing data
regarding smoking status and quality control, MRI data from 143
PD patients [72 non-smokers (PD/NS) and 71 smokers (PD/S)] and
178 HC participants [116 non-smokers (HC/NS) and 62 smokers
(HC/S)] were included in the present analysis (see Figure S1 in
the supplement). Sociodemographic and clinical characteristics
of the final, ‘quality controlled’ sample are shown in Table 1. The
study was approved by the ethics committees of all participating
universities. All subjects gave written, informed consent before
participating in the study.
MRI acquisition
MRI data were acquired using 3T scanners. The following
scanners were used: a 3T Philips Achieva scanner (Philips
Medical Systems, Best, The Netherlands) in Münster; a 3T
Siemens Trio scanner (Siemens AG, Erlangen, Germany) in
Dresden and Marburg; a 3T Siemens Verio scanner (Siemens
AG, Erlangen, Germany) in Greifswald; a 3T General Electric
Healthcare scanner (General Electric Healthcare, Milwaukee,
WI) and a 3T Siemens Trio scanner in Berlin. MP-RAGE
T1-weighted images were acquired with the following param-
eters: voxel size= 1×1×1 mm3; repetition time (TR) = 1900 ms;
inversion time (TI) = 900 ms; field of view (FOV) = 256 × 256 mm2;
slices per slab=176; thickness=1 mm; flip angle= 9, echo time
(TE) = 2.26 ms.
Preprocessing and statistical analyses
We used SPM12 (www.fil.ion.ucl.ac.uk) and the CAT12 toolbox
(http://www.neuro.uni-jena.de/cat/) implemented in MATLAB
R2016a (MathWorks, Sherborn, MA) to pre-process and analyze
the neuroimaging data. Brain scans were segmented in gray
matter, white matter and cerebrospinal fluid and subsequently
normalized to the Montreal Neurological Institute reference
brain in CAT12. The voxel size was re-sampled to 1.5 × 1.5 ×
1.5 mm3 during this step. The resulting images were quality
controlled via visual inspection and CAT12-based outlier checks
(homogeneity analysis). All scans that were scored as having
low quality in one of the assessments were rejected, which lead
to the exclusion of n =16 subjects. Scans from the remaining
subjects were smoothed with an 8 mm full-width at half-
maximum Gaussian kernel. To confirm pervious findings,
we investigated the effect of smoking in HC subjects on a
whole-brain level ‘as well as in specific regions pertaining
to the pathophysiology of smoking and PD’ (HC/S<HC/NS).
Subsequently, we examined our a priori defined hypothesis
if actual smoking status confounds differences in specific
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fronto-limbic circuitry and on a whole-brain level between HC
subjects and PD patients by conducting t-tests for the smoker
and non-smoker groups separately [PD<HC (non-smokers
only); PD<HC (smokers only)]. In addition, we examined
in an explorative manner the main and interaction effects
of smoking and diagnosis [(PD<HC (whole sample); S<NS
(whole sample); S<NS (PD only); PD<HC (non-smokers <
smokers)]. Furthermore, an explorative analysis on white matter
volume differences in pre-defined regions of interest (ROIs) was
performed using the above-mentioned contrasts. Age, gender,
education, total intracranial volume, study center and Beck
Depression Inventory (BDI-II; Beck et al., 1996) scores were
included as covariates of no interest. For all analyses, an implicit
mask with an absolute threshold of 0.15 was applied, allowing
us to include only those voxel showing an increased probability
to contain the analyzed tissue type. An anatomical ROI of the a
priori defined brain areas (amygdala, ACC, hippocampus, insula,
thalamus, OFC) was calculated combining the definitions from
the Automated Anatomical Labeling Atlas (Tzourio-Mazoyer
et al., 2002) as implemented in the Wake Forest University
PickAtlas (Maldjian et al., 2003) in SPM12 in one mask. Small
volume correction on this ROI masks was applied using a
cluster-forming threshold of P<0.001 on the voxel level and
a clusterwise familywise error-corrected threshold of Pfwe <0.05
with a minimum cluster size of k =10 contiguous voxels. For the
exploratory whole-brain analysis, as recommended in cluster-
extent-based thresholding in fMRI analysis (Woo et al., 2014),
a cluster-extent threshold was applied to correct for multiple
comparisons using P<0.001 as significance threshold on the
voxel level and k =200 contiguous voxels on the cluster level. In
addition, we performed Pearson’s correlation analyses between
significant reduced GMV in PD patients (PD<HC) identified in
our ROI analysis and clinical scores (Hamilton Anxiety Scale and
Panic and Agoraphobia Scale). To further examine an additive
effect of smoking and PD, we conducted a linear regression
model in SPM using three groups with increasing health burden
(group 1: neither PD nor smoking; group 2: either PD or smoking;
group 3: both PD and smoking) as independent variable. We
examined a positive and negative linear effect on the previous
identified brain regions of the group analysis only.
Results
Sample characteristics
Smokers were significantly more frequent in PD patients than
in HC subjects [χ2 (1) = 7.176, P =0.007]. Demographic data and
clinical characteristics are shown in Table 1, where differences
within the smoker and non-smoker groups (PD/S vs HC/S and
PD/NS vs HC/NS) are reported. Age, gender and handedness
were matched between the two diagnostic groups (PD vs HC)
and did not significantly differ. However, there was a difference
regarding the years of education,withHC subjects showingmore
years of education than PD patients irrespective of their smoking
status. For that, education was added as covariate of no interest
in the models. Regarding the clinical characteristics of the PD
patient sample only (PD/S vs PD/NS), PD/S showed trend wise
higher Brief Symptom Inventory and BDI-II scores, reflecting
the previously reported association of smoking with symptom
severity (Zvolensky et al., 2005). Furthermore, significantly more
PD/S suffered from a comorbid depressive disorder ( Table 1), for
that, we included the BDI-II scores as covariate of no interest
in the models. Based on the 12-month prevalence, assessed
by the clinical interview, 20 PD/S patients were characterized
as nicotine dependent according to DSM-IV criteria and six
PD/NS patients presented nicotine dependence within the past
12 months and can be characterized as ex-smoker.
VBM: ROI analysis
Compared to non-smokers, we identified significant regional
GMV reductions in smokers in the right insula cortex and ACC
in HC subjects (Table 2). Investigating the modulating impact
of smoking on PD pathophysiology, only in non-smokers, PD
patients showed significantly reduced regional GMV in the bilat-
eral amygdalae and hippocampi compared to non-smoking HC
subjects. In the smoker group, no main effect of diagnosis could
be shown (Figure 1 and Table 2).
Irrespective of smoking status, a GMV reduction in the
right amygdala was identified in the PD group compared to
HC subjects in our explorative conducted ROI analysis (Figure 1
and Table 2). Furthermore, we found significant smaller regional
GMV in smokers compared to non-smokers regardless of
diagnosis in the left orbitofrontal gyrus, the right insular cortex
and the left ACC. Regarding PD patients, a significant GMV
reduction could be obtained in the left thalamus in smokers
compared to non-smokers. No significant effects could be
obtained in the exploratory conducted interaction analysis
(Table 2).
However,we found a significant negative correlation between
Structured Interview Guide for the Hamilton Anxiety Scale
(SIGH-A) scores and the right amygdala volume (r =−0.173,
P =0.040) only in the group of non-smokers [PD<HC (non-
smokers only)]. When smokers of both groups were included
in the analysis, the correlation was not significant (r =−0.098,
P =0.107). No other significant correlations could be obtained
between the right amygdala and the other clinical scores
(Figure 1 and Table 3).
Analyses of white matter volume revealed no significant
alterations in smokers compared to non-smokers and in PD
patients compared to HC subjects in the a priori defined ROIs.
VBM: explorative whole-brain analysis
In the HC group, significant regional GMV reductions were found
in smokers compared to non-smokers in the right fusiform
gyrus, the right precentral gyrus, the left precentral gyrus and
the right supplementary motor area (Table 4).
Related to HC/NS subjects, PD/NS patients showed signifi-
cantly reduced regional GMV in the left and right parahippocam-
pal area and the right cerebellum. No significant differences in
GMV could be obtained for PD/NS>HC/NS. In the smoker group
only, no main effect of diagnosis could be shown (Table 4).
The exploratory conductedmain effect of diagnosis, irrespec-
tive of smoking status, showed a significant reduced GMV in
PD patients in the left middle temporal gyrus (Table 4). Irrespec-
tive of diagnosis, we found significant smaller regional GMV in
smokers compared to non-smokers in the right fusiform gyrus,
the right and left precentral gyrus, the left orbitofrontal gyrus
inclusive ACC and in the left middle frontal gyrus (Table 4). No
additional structural alterations were identified in PD/S patients
compared to PD/NS patients on a whole-brain level. The interac-
tion analysis of smoking and diagnosis revealed no significant
results.
Regression analyses
We performed a regression analysis to examine a potential
additive effect of health burden on the previous identified brain
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Table 2. Locations of significant gray matter volume differences identified in the ROI analysis in PD and HC subjects as a function of smoking
status on peak level with MNI coordinates of local maxima
Contrast/region Side Cluster size in voxel x y z t-value P FWE corrected
S<NS (healthy controls only)
Insula R 60 42 0 8 3.95 0.002
ACC R 16 14 47 12 3.05 0.034
S>NS (healthy controls only) No differential effect
PD<HC (non-smokers only)
Amygdala L 92 −18 0 −22 3.71 0.003
Amygdala R 101 24 0 −22 3.69 0.003
Hippocampus L 10 −18 −4 −22 3.34 0.038
Hippocampus R 30 −2 −22 3.70 0.013
PD>HC (non-smokers only) No differential effect
PD<HC (smokers only) No differential effect
PD>HC (smokers only) No differential effect
PD<HC (whole sample)
Amygdala R 25 24 0 −22 3.36 0.022
PD>HC (whole sample) No differential effect
S<NS (whole sample)
Orbitofrontal gyrus L 134 −6 42 −12 3.84 0.001
Insula R 27 −2 4 3.37 0.049
ACC L 20 −6 45 −4 3.28 0.050
S>NS (whole sample) No differential effect
S<NS (PD only)
Thalamus L 50 −4 −8 14 3.54 0.001
S>NS (PD only) No differential effect
Interaction of smoking and diagnosis No differential effect
Notes: PD, panic disorder; HC, healthy control; ROI, region of interest; NS, non-smoker; S, smoker; L, left; R, right; x, y, z, MNI coordinates; MNI, Montreal Neurological
Institute; ACC, anterior cingulate cortex; FWE, familywise error.
P< 0.05 FWE corrected with a minimum cluster size of 10 voxel.
Table 3. Pearson’s correlation analyses between significant reduced
GMV in PD patients compared to HC subjects identified in the ROI
analysis with clinical scores
SIGH-A (p) PAS (p)
Amygdala R (non-smoker) −0.173 (0.040)∗ −0.076 (0.295)
Amygdala R (whole group) −0.098 (0.107) −0.076 (0.295)
Notes: GMV, gray matter volumes; PD, panic disorder; HC, healthy control; ROI,
region of interest; SIGH-A, Hamilton Anxiety Scale; PAS, Panic and Agoraphobia
Scale; R, right.
Missing values in HC subjects: SIGH-A: 48; PAS: 31.
regions. We found a linear decrease in the left and right amyg-
dala with increasing health burden in the ROI analysis (Figure 2
and Table 5 as well as Figure S2 in the supplement).
Results did not change when excluding the six ex-smokers
from the group of PD/NS.
Discussion
As supported by the present findings, smoking behavior is highly
prevalent in PD patients. Structural abnormalities characterizing
the neurobiology of smoking do, to some extent, overlap with
brain circuits involved in the pathophysiology of PD. Despite
this high co-occurrence, the modulating impact of smoking
on regional gray matter abnormalities in PD patients was
not explicitly targeted before. Present findings partly confirm
pervious identified morphological differences between healthy
smokers and non-smokers and indicate that GMV reductions
in the amygdala and hippocampus commonly associated
with PD pathophysiology are mainly driven by non-smokers.
These effects appear to diminish in smokers, which can be
attributed to already reduced GMV in healthy smoking subjects.
Furthermore, bilateral amygdala volumes show a linear decrease
with increasing health burden, possibly indicating additive
effects of smoking and PD.
Regarding PD patients, GMV reductions in the bilateral
amygdalae and hippocampi were more pronounced in the
non-smoker group only than in the combined sample. Fur-
thermore, comparing the smoker group of PD patients and
HC subjects yielded comparable GMV in the above-mentioned
brain structures. Results of the correlation analysis support
this finding. We found a non-significant relationship between
amygdala volume and SIGH-A scores, when smokers of both
groups were included in the analysis and a significant negative
relation in non-smokers only. GMV reductions in the amygdala
and hippocampus can be related to the pathophysiology of
PD, evidenced by previous research (Del Casale et al., 2013;
Pannekoek et al., 2013). These findings on a morphological
level can be matched by the presence of neurochemical
alterations. PD patients demonstrate lower N-acetylaspartate in
the hippocampus (Trzesniak et al., 2010), and reduced binding
properties for the serotonin 5-HT1A receptor are evident in
the amygdala and hippocampus in PD patients (Nash et al.,
2008). Considering the results of the whole-brain approach,
the parahippocampal gyrus, a brain region linked to the patho-
physiology of PD in several previous studies (Del Casale et al.,
2013; Dresler et al., 2013), was significant only when smokers of
both groups were excluded from the analysis. Findings indicate
that current smoking has indeed a modulating impact on brain
morphological correlates in PD patients potentially blurring
group differences associated with psychopathology. We thus
conclude that current smoking behavior in PD patients and HC
subjects can narrow or diminish commonly observed structural
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Fig. 1. (A): Main effect of PD on GMV across the whole sample of PD patients and HC subjects. PD patients show reduced volumes compared to HC participants in the
right amygdala. ‘No significant correlation between GMV and SIGH-A scores’. (B): Significant differences between HC/NS and PD/NS in the right amygdala. Reduced
GMVs are negatively correlated with SIGH-A scores. Bars represent the estimated gray matter volumes of the corresponding brain region; error bars represent SEM.
R= right. ∗P< 0.05; ∗∗P< 0.001.
abnormalities in PDpatients. If this confounder is not considered
by matching or as a covariate, which was the case in previous
examinations (i.e. Massana et al., 2003; Asami et al., 2009, 2018;
Hayano et al., 2009; Uchida et al., 2003), findings on structural
abnormalities in PD patients pertaining to key regions involved
(e.g. amygdala and hippocampus) may be biased. As such, it
can be speculated if previous studies including both smoking
and non-smoking subjects may even have underestimated
the true effect of volume reduction in the amygdala and
hippocampus.
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Table 4. Locations of significant gray matter volume differences identified in the whole-brain analysis in PD and HC as a function of smoking
status on peak level with MNI coordinates of local maxima
Contrast/region Side Cluster size
in voxel
x y z t-value P uncorrected
S<NS (healthy controls only)
Fusiform gyrus R 847 28 −42 −18 4.33 <0.001
Precentral gyrus L 761 −24 −21 69 4.20 <0.001
Precentral gyrus R 521 46 −15 56 4.17 <0.001
Supplementary motor area R 222 2 −2 48 3.69 <0.001
S>NS (healthy controls only) No differential effect
PD<HC (non-smokers only)
Parahippocampal area R 552 0 −22 3.76 0.001
Parahippocampal area L 210 −18 0 −22 3.76 <0.001
Cerebellum R 409 32 −75 −50 3.57 <0.001
PD>HC (non-smokers only) No differential effect
PD<HC (smokers only) No differential effect
PD>HC (smokers only) No differential effect
PD<HC
Middle temporal gyrus L 267 −40 6 −27 3.97 <0.001
PD>HC No differential effect
S<NS (whole sample)
Fusiform gyrus R 1463 28 −45 −16 5.20 <0.001
Precentral gyrus L 337 −36 −16 60 3.71 <0.001
Precentral gyrus R 325 38 −20 42 3.99 <0.001
Orbitofrontal gyrus inclusive
ACC L 208 −6 42 −12 3.84 <0.001
Middle frontal gyrus L 219 −21 21 48 3.72 <0.001
S>NS (whole sample) No differential effect
S<NS (PD only) No differential effect
S>NS (PD only) No differential effect
Interaction of smoking and diagnosis No differential effect
Notes: PD, panic disorder; HC, healthy control; NS, non-smoker; S, smoker; L, left; R, right; x, y, z, MNI coordinates; MNI, Montreal Neurological Institute; ACC, anterior
cingulate cortex.
P< 0.001 uncorrected with a minimum cluster size of 200 voxels.
Across thewhole sample, PD patients exhibited reduced GMV
in a subcortical brain structure compared to HC participants.
Studies with different functional and structural imaging
modalities have consistently reported abnormalities of the
amygdala in PD patients, consistent with animal work on fear
conditioning and prominent neuroanatomical models of PD
(Gorman et al., 2000; Pannekoek et al., 2013). Reduced amygdala
volumes in PD patients may represent the structural basis
of the functional abnormalities that have been reported in
the neuroimaging literature (Sakai et al., 2005; Pillay et al.,
2006; Nash et al., 2008; Chechko et al., 2009; Tuescher et al.,
2011).
To further examine if smoking results in an additive effect
on the previously identified brain structures, we conducted a
regression model. Considering three groups with increasing
health burden, a linear negative effect of decreasing GMV
with increasing burden was observed for bilateral amygdalae
volumes, suggesting that the combined impact of health burden
(smoking and PD) may be reflected in the structure of the
amygdalae. Previous research linked structural alterations of
this brain region to both conditions (Dresler et al., 2013; Durazzo
et al., 2017). However, alternatively it needs to be considered
that the observed GMV reductions in the amygdalae may have
existed even before subjects began smoking and developing
panic symptoms and PD. Reduced GMV in the amygdalae could
therefore also represent a potentially predisposing factor to
smoking behavior or PD, or a shared factor for the development
of both conditions.
Considering the HC group, GMV reductions in smokers with
respect to the ‘insula, ACC’ and fusiform gyrus are consistent
with results from previous VBM investigations (Brody et al., 2004;
Gallinat et al., 2006; Yu et al., 2011; Liao et al., 2012; Stoeckel et al.,
2016). When evaluating the whole sample, smoker showed sig-
nificant GMV reductions in ‘prefrontal cortex’ regions identified
in various studies before, like in theOFC andmiddle frontal gyrus
(Brody et al., 2004; Morales et al., 2012; Fritz et al., 2014), which
have been related to the neurobiology of substance addiction,
including smoking (Goldstein and Volkow, 2002).
Cigarette smoke components, including nicotine and free
radicals, facilitate negative effects on various neurotransmitter
systems, neurobiology, the respiratory system and normal neu-
rodevelopmental processes (Niedermaier et al., 1993; Zvolensky
et al., 2003; Dwyer et al., 2008; Moylan et al., 2013). Evidence into
the pathogenesis of PD supports a role of these developments
(Moylan et al., 2013). The importance of specific neurotrans-
mitter systems has been extensively demonstrated in anxi-
ety disorders, with current first-line pharmacological therapies
interacting predominantly with the serotonergic, noradrenergic,
cannabinoid, cholinergic and dopaminergic systems (Moylan
et al., 2013). However, some of these agents are also effective in
enhancing smoking cessation (Jorenby et al., 1999), suggesting
a plausible biological interaction between these systems and
nicotine dependence. Furthermore, free radicals, another highly
concentrated component of cigarette smoke, were linked to a
relative deficit in both, tryptophan and serotonin, which could
be related to increased anxiety symptoms (Bell et al., 2005; Kulz
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Fig. 2. Linear negative association between health burden and bilateral amygdalae GMV. Bars represent the estimated gray matter volumes of the corresponding brain
region; error bars represent SEM. R= right, L = left. ∗P< 0.05.
Table 5. Regression analysis of the whole sample, separated in three groups with increasing burden of health (group 1: neither PD nor smoking;
group 2: either PD or smoking; group 3: both PD and smoking)
Side Cluster size
in voxel
x y z t-value P FWE
corrected
Linear negative effect
Amygdala L 22 −29 5 −18 3.80 0.017
Amygdala R 57 29 5 −21 4.4 0.010
Linear positive effect No differential effect
Notes: PD, panic disorder; L, left; R, right; x, y, z, MNI coordinates; MNI, Montreal Neurological Institute; FWE, familywise error.
Cluster represents region of interest analysis with a cluster-based threshold of P< 0.05 FWE corrected and with a minimum cluster size of 10 voxel.
et al., 2007). Numerous population-based studies demonstrated
smoking as being prospectively associated with increased rates
of anxiety disorders and PD (Breslau and Klein, 1999; Johnson
et al., 2000). The effects caused by cigarette smoking may at least
partially underpin the biological mechanisms through which
smoking might contribute to the development of PD. Hence, it
can be speculated that smoking may act as a brain structural
vulnerability factor. Like on neurotransmitter systems, smoking
cigarettes impacts on specific brain structures also involved
in the pathogenesis of PD and thereby possibly predisposing
smokers for the development of anxiety symptoms and PD.
Conversely, nicotine can exert an anxiolytic effect as well
through rapid desensitization of nicotine acetylcholine recep-
tors in the brain (Gentry and Lukas, 2002; Picciotto et al., 2008)
and thereby reduce anxiety symptoms, known as the theory
of self-medication or self-treatment. Evidence supports that
nicotine exposure does produce a subjective calming effect,
although this is coupled with an increase in objective measures
of physiological arousal (Perkins, 1995), which could contribute
to the maintenance or an increased frequency of smoking in PD
patients.
However, as our study is limited by its cross-sectional design,
longitudinal studies are clearly needed to assess the role of
smoking as a potential marker of vulnerability for PD on a brain
structural level.
Although our study benefits from a large sample size, we
have to consider some limitations. The study was not primarily
designed to examine the effect of smoking, so we had only lim-
ited data available on smoking behavior; though a more detailed
assessment of smoking severity, history and dependence could
shedmore light on the observed differences. Furthermore, smok-
ing status was based exclusively on self-report and was not
verified by parameters like CO levels or plasma cotinine. As all
patientsweremedication-free, the interaction of cigarette smok-
ing and selective serotonin re-uptake inhibitor (SSRI) treatment
could not be investigated. Smokers differ from non-smokers
in pharmacokinetics (Zevin and Benowitz, 1999; Kroon, 2007),
thus it is plausible to assume an additional interaction with
SSRI treatment on symptomatology and possibly brain structure
and function. As SSRIs are a first-line treatment, studying the
interaction effects with smoking in PD patients would be of
relevance from an ecological validity perspective. Significantly
more PD/S patients suffered from a comorbid depressive disor-
der, which seems plausible, considering the link between smok-
ing and symptom severity (Covey et al., 1998; Zvolensky et al.,
2005), although our effects remained stable after controlling
for depressive symptom scores (BDI-II). Because of the cross-
sectional design of our study, we cannot exclude the possibility
of any pre-existing structural differences between the analyzed
smokers and non-smokers as well as between HC participants
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and PD patients. As our study represents a preliminary inves-
tigation of the modulating impact of actual smoking behavior
on commonly established brain structures in PD patients, future
studies are encouraged to investigate this interaction in more
depth, including elaborate measures on smoking behavior.
We conclude that current cigarette smoking impacts on neu-
ral pathways associated with PD pathophysiology in smokers,
differences in GMV reductions in the amygdala and hippocam-
pus diminished. In line, we could demonstrate an additive effect
of smoking and PD on amygdalae volumes, a brain structure
involved in both, the pathophysiology of PD and nicotine depen-
dence. From amethodological perspective, current smoking sta-
tus should be considered as an important covariate in future
neuroimaging studies focusing on PD. From amechanism-based
perspective, the frequently observed co-occurrence of smoking
and PD may be reflected by partly overlapping neurostructural
correlates. Longitudinal studies are needed to assess whether
smoking (which onset precedes the one of PD) may confer its
risk properties also via the neural systems level. Early preventive
approaches on smoking cessation particularly in PD vulnerable
individuals may specifically ameliorate the adverse effects of
smoking also on a neural systems level.
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